Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative bioavailability study of MK-3682A fixed-dose combination tablet formulations
NL-OMON42602Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of uprifosbuvir, grazoprevir and verubecestat in hepatitis C virus infection (4 arms), sponsored by Merck & Co. Primary endpoint: Comparative bioavailability and pharmacokinetics of MK-3682 and metabolites. Started Jun 2015; status: active, not recruiting.
02
Drugs
uprifosbuvirgrazoprevirverubecestat
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON42602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42602.